MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Medtronic PLC (MDT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive analyst sentiment, and upcoming product launches in multi-billion dollar markets. While technical indicators are mixed, the long-term growth potential outweighs short-term uncertainties.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 39.167. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an upward trend in the longer term. Key support is at $99.464, and resistance is at $104.72, with the current pre-market price at $100.98, close to support levels.
Analysts have issued several upgrades and increased price targets, with many citing new product launches and improved execution as key drivers.
Hedge funds are significantly increasing their positions in MDT, with a 167.88% rise in buying activity last quarter.
Financials show strong YoY growth in revenue (6.64%), net income (8.19%), and EPS (8.08%).
Medtronic has achieved its 48th consecutive dividend increase, signaling stability and shareholder value.
Insiders are selling shares, with a 288.10% increase in selling activity over the last month.
Congress members have made four sale transactions in the last 90 days, indicating cautious sentiment.
The MACD indicator is bearish, and the stock has a 50% chance of declining slightly in the short term (-0.01% next day, -5.46% next month).
In Q2 FY2026, Medtronic reported a 6.64% YoY revenue increase to $8.96B, an 8.19% YoY net income increase to $1.37B, and an 8.08% YoY EPS increase to $1.07. Gross margin improved to 60.67%, up 0.85% YoY. These figures indicate healthy growth and operational efficiency.
Analysts are broadly positive on MDT, with several upgrades and price target increases. Notable ratings include Needham's upgrade to Buy with a $121 target, Citi's Buy rating with a $117 target, and Wells Fargo's Overweight rating with a $114 target. Analysts highlight new product launches, improved execution, and Elliott Management's involvement as key growth drivers.
